There is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
| Orders | Qty | Bid |
|---|---|---|
| Ask | Qty | Orders |
|---|---|---|
Our researchers has found no immediate positive insights for this stock. We'll update this space as soon as we find something.
Eris Lifesciences Limited is a publicly listed Indian pharmaceutical company incorporated on January 25, 2007. It manufactures and markets prescription medicines with a sharp focus on specialty and super-specialty therapies, and ranks 20th in the Indian Pharmaceutical Market, the youngest among the Top-20 firms.
Its core strengths span Oral Anti-Diabetes, Insulins, Cardiovascular, Vitamins/Minerals/Nutrients (VMN) and Dermatology, with rapid expansion into Nephrology, Critical Care, Women’s Health and Oncology . The Group operates manufacturing across six globally accredited/compliant units, with recent facilities designed to meet EU-GMP, PIC/s and key Latin American agency requirements; it is moving from an “India-only” business to “India + RoW Exports” with Swiss Parenterals as its international arm . The company’s integrated R&D centre in Ahmedabad houses over 40 qualified scientists in an 11,000 sq. ft facility supporting end-to-end development across sterile injectables, complex injectables, ophthalmics, topicals and oral dosage forms.
As on March 31, 2025, Eris had 8 subsidiaries (not listed here as requested) and 1 joint venture . Key milestones in the latest year include successful integration of Biocon’s India Branded Formulations business, the acquisition of a biologics drug products facility (Eris BioNxt), a 30% strategic stake in Levim Lifetech, EU-GMP/ANVISA inspections across units, and first-in-market fixed-dose combination launches in Diabetes and Cardio-metabolic care .
– Share of Domestic Branded Formulations: 87%of total revenue .
– Therapy-wise contribution (Source: AWACS MAT Mar’25): Oral Anti-Diabetes 23%; Insulins 9%; Cardiovascular 16%; VMN 14%; Dermatology 12%; Women’s Health 6%; CNS 5%; Critical Care 4%; Nephrology 3%; Oncology 1%; Rest 7% .
– Amit Bakshi – Chairman and Managing Director
– Krishnakumar V – Executive Director & Chief Operating Officer
– Inderjeet Singh Negi – Whole Time Director
– Kaushal Shah – Whole Time Director
– Sachin Shah – Chief Financial Officer
– Milind Talegaonkar – Company Secretary and Compliance Officer
– Integration and portfolio expansion: All businesses acquired from Biocon Biologics were integrated into the Branded Formulations business, strengthening Insulins, Critical Care, Nephrology and Oncology franchises. The acquisition of Biocon’s India-branded formulations business was executed for Rs 1,242 crore via slump sale, with purchase price allocation completed under acquisition accounting .
– Biologics manufacturing footprint: A biologics fill-finish facility at Bhopal was acquired to insource insulin manufacturing; it is approvable by EU-GMP, PIC/s and Latin American regulators. Eris also acquired Eris BioNxt (formerly Chemman Labs) to handle Insulins, GLP-1s, MABs and rDNA products, and invested in Levim Lifetech for biologics bulk substance capabilities, with a cumulative capital outlay of nearly Rs 200 crore for the Chennai biologics build-out .
– International readiness: Multiple facilities have been designed/brought up to EU-GMP, PIC/s and key LatAm standards; Ahmedabad units were inspected by Brazil’s ANVISA, supporting Eris’s transition to “India + RoW Exports” .
– R&D and launches: The company executed “first-in-market” fixed-dose combination launches in FY25 (e.g., Dapagliflozin + Bisoprolol; Dapagliflozin + Metoprolol; Dapagliflozin + Pioglitazone) and progressed a 25+ candidate Oral Solids pipeline alongside a Diabesity pipeline of Insulin Analogues, GLP-1s and combinations for FY26–FY28 .
Eris manufactures and markets prescription pharmaceuticals across specialty and super-specialty therapies, with leadership in cardio-metabolic care and growing portfolios in Dermatology, Women’s Health, Critical Care, Nephrology and Oncology .
As on March 31, 2025, Eris had 8 subsidiaries and 1 joint venture; only the number is disclosed here in line with your request .
The Group operates manufacturing across six globally accredited/compliant units in India, with facilities designed for EU-GMP, PIC/s and Latin American compliance; Swiss Parenterals is the international arm as Eris expands to RoW exports. Its Ahmedabad units were inspected by ANVISA, reflecting readiness for large international markets .
